Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
about
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Cancer therapy with phytochemicals: evidence from clinical studiesMicrotubule-binding agents: a dynamic field of cancer therapeutics.A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor modelsSegmentation of dynamic contrast enhanced magnetic resonance imaging data.A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumoursAnti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and ExamplesDesign, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4.Synthesis and antiproliferative activities of ottelione a analoguesIn vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.Anti-angiogenesis therapies: their potential in cancer managementA phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcomePhase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model.Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output.Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancerMultiparametric MRI biomarkers for measuring vascular disrupting effect on cancerA dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumorsVascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphateA perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentDesign, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4.Reproducibility of CT perfusion parameters in liver tumors and normal liver.Cardiovascular toxicity profiles of vascular-disrupting agents.Dependence of DCE-MRI biomarker values on analysis algorithm.Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.Naphthalene combretastatin analogues: synthesis, cytotoxicity and antitubulin activity.Imaging angiogenesis: applications and potential for drug development.The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Thyroid cancer: pathogenesis and targeted therapyPhase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.Epothilones in the treatment of cancer.Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.Vascular disrupting agents in clinical development
P2860
Q24642049-9940BF0A-B00C-4F2C-B9E3-619BD41E4BE9Q26751344-88D1EE97-1FB9-4E13-9043-429F466AF8C7Q26781365-9F40A03D-853B-4BCA-9330-F977B7DE9498Q26827407-E3CB6A23-6A2A-4770-AC5D-E8D00E87FE09Q27690249-D001320D-D2D3-442C-94DF-C6C970849E53Q28543671-3DFBBE49-F023-4090-A93D-288C932F8386Q31165580-7A52C136-6437-4C9F-8971-8C203C800750Q33159659-DE124F92-3A95-4FCC-9F3D-694E0E0734E0Q33265941-1ED8B139-0176-4003-9F59-3B18D49DD135Q33389126-6962CA88-E73B-4AB9-A816-8B305DCCEDF8Q33393879-C0430221-3B25-4C5E-9675-9BF39CFCA413Q33510695-5958DA87-EEF3-44E6-887B-717B44CCFDE6Q33606508-21E6DB7A-7244-4776-87DF-5E93A9DCF5BDQ33630497-71C001CE-1BAA-4F09-AA75-8A640C57E941Q33827707-22DCFAC1-E667-4106-BFFC-8CC7F58C933AQ33956056-08FCF9AC-B06C-4E65-8000-A541188A4C34Q34035391-250A486A-20B1-45E2-89F9-9D7DAAF87225Q34122854-561C024F-C3CB-4AF3-A4D5-38BEDB61DAC4Q34208140-C33AA837-5C30-44B5-805E-6D72031D938DQ34219595-6EEE7762-DB20-4FB6-8FD2-5F55DFFC3CFBQ34279269-96074342-15BA-4E7A-A269-57AEA4452802Q34390068-6F7226FF-6C3A-4EDC-8D15-697E00A7E892Q34538659-AC2399A9-12BB-4A59-A488-BAD9B88012EEQ34546774-44FE40EB-84E3-4456-8A0E-B41F99737FBDQ34547313-9E9AFCF2-5EE6-44BA-8C2F-485652448F89Q34765364-C1662F53-CC95-484F-BABC-287C2A375FBFQ35092318-DD7C58BD-75BA-4B2C-8CF8-805E1078D42DQ35167394-A228EF0A-33BF-4FBD-93D8-1C4477C00774Q35584746-3B3F2C0A-DE5B-491B-971C-9A5FEB6EFFC1Q35711964-F5847BA3-3A41-4AD8-B980-FD53E69D039FQ35855949-3C2351E4-1378-4B7B-8807-010B7E0B2B2BQ36016221-49AAA756-085E-4803-9F89-8F04EB4CA6BFQ36027611-08F16342-0D77-4C78-BA46-B136D651D815Q36213741-B70F6122-9BAE-4E16-A1E2-74C06A6EB2F3Q36328045-01421FE3-BC7B-44DF-9660-9C7167DD675FQ36482522-4A2E382D-F1D1-4C73-8679-30950DE8DE7BQ36491842-17806F7B-832B-4560-AC4E-DD70E65A6799Q36615531-C35690ED-0DA2-4E9E-B43F-FBC9BFFFD109Q36702766-0C9590D4-134D-4244-ABAD-30CB46187C04Q36765436-42E45380-8F17-46B6-A85B-3725EEB141FC
P2860
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Phase I trial of the antivascu ...... for altered tumor blood flow.
@ast
Phase I trial of the antivascu ...... for altered tumor blood flow.
@en
type
label
Phase I trial of the antivascu ...... for altered tumor blood flow.
@ast
Phase I trial of the antivascu ...... for altered tumor blood flow.
@en
prefLabel
Phase I trial of the antivascu ...... for altered tumor blood flow.
@ast
Phase I trial of the antivascu ...... for altered tumor blood flow.
@en
P2093
P356
P1476
Phase I trial of the antivascu ...... for altered tumor blood flow.
@en
P2093
Bruce Giantonio
Daniel G Haller
David Chaplin
David Vaughn
James P Stevenson
Mark Rosen
Maryann Gallagher
Michael Stratford
Mitchell Schnall
Peter J O'Dwyer
P304
P356
10.1200/JCO.2003.12.986
P407
P577
2003-12-01T00:00:00Z